The Experts below are selected from a list of 71991 Experts worldwide ranked by ideXlab platform

Joon Won Park - One of the best experts on this subject based on the ideXlab platform.

  • Nanotechnology for Early Cancer Detection
    Sensors, 2010
    Co-Authors: Young Eun Choi, Ju Won Kwak, Joon Won Park
    Abstract:

    Vast numbers of studies and developments in the nanotechnology area have been conducted and many nanomaterials have been utilized to detect Cancers at Early stages. Nanomaterials have unique physical, optical and electrical properties that have proven to be very useful in sensing. Quantum dots, gold nanoparticles, magnetic nanoparticles, carbon nanotubes, gold nanowires and many other materials have been developed over the years, alongside the discovery of a wide range of biomarkers to lower the Detection limit of Cancer biomarkers. Proteins, antibody fragments, DNA fragments, and RNA fragments are the base of Cancer biomarkers and have been used as targets in Cancer Detection and monitoring. It is highly anticipated that in the near future, we might be able to detect Cancer at a very Early stage, providing a much higher chance of treatment.

Casey Burton - One of the best experts on this subject based on the ideXlab platform.

  • a rebuttal to a comment to normalization of urinary pteridines by urine specific gravity for Early Cancer Detection clin chim acta 435 2014 42 47
    Clinica Chimica Acta, 2015
    Co-Authors: Casey Burton
    Abstract:

    Abstract We really appreciate the comments from Drs. Reibnegger and Fuchs regarding our recent publication “Normalization of urinary pteridines by urine specific gravity for Early Cancer Detection [Clin. Chim. Acta 435 (2014) 42–47]”. In their letter, Drs. Reibnegger and Fuchs identify several potential concerns regarding our recent publication [1] that evaluated the normalization performance of urine specific gravity (USG) and urinary creatinine with respect to the diagnostic properties of selected pteridines in discerning aggressive and benign breast Cancers. Their letter not only provides unique insights that are both relevant and helpful to many researchers engaging in similar studies, but also provides a wonderful opportunity for us to address these potential concerns that may also be shared by other readers. We addressed all of the comments by Drs. Reibnegger and Fuchs in this letter.

  • normalization of urinary pteridines by urine specific gravity for Early Cancer Detection
    Clinica Chimica Acta, 2014
    Co-Authors: Casey Burton
    Abstract:

    Abstract Background Urinary biomarkers, such as pteridines, require normalization with respect to an individual's hydration status and time since last urination. Conventional creatinine-based corrections are affected by a multitude of patient factors whereas urine specific gravity (USG) is a bulk specimen property that may better resist those same factors. We examined the performance of traditional creatinine adjustments relative to USG to six urinary pteridines in aggressive and benign breast Cancers. Methods 6-Biopterin, neopterin, pterin, 6-hydroxymethylpterin, isoxanthopterin, xanthopterin, and creatinine were analyzed in 50 urine specimens with a previously developed liquid chromatography–tandem mass spectrometry technique. Creatinine and USG performance were evaluated with non-parametric Mann–Whitney hypothesis testing. Results USG and creatinine were moderately correlated (r = 0.857) with deviations occurring in dilute and concentrated specimens. In 48 aggressive and benign breast Cancers, normalization by USG significantly outperformed creatinine adjustments which marginally outperformed uncorrected pteridines in predicting pathological status. In addition, isoxanthopterin and xanthopterin were significantly higher in pathological specimens when normalized by USG. Conclusion USG, as a bulk property, can provide better performance over creatinine-based normalizations for urinary pteridines in Cancer Detection applications.

Young Eun Choi - One of the best experts on this subject based on the ideXlab platform.

  • Nanotechnology for Early Cancer Detection
    Sensors, 2010
    Co-Authors: Young Eun Choi, Ju Won Kwak, Joon Won Park
    Abstract:

    Vast numbers of studies and developments in the nanotechnology area have been conducted and many nanomaterials have been utilized to detect Cancers at Early stages. Nanomaterials have unique physical, optical and electrical properties that have proven to be very useful in sensing. Quantum dots, gold nanoparticles, magnetic nanoparticles, carbon nanotubes, gold nanowires and many other materials have been developed over the years, alongside the discovery of a wide range of biomarkers to lower the Detection limit of Cancer biomarkers. Proteins, antibody fragments, DNA fragments, and RNA fragments are the base of Cancer biomarkers and have been used as targets in Cancer Detection and monitoring. It is highly anticipated that in the near future, we might be able to detect Cancer at a very Early stage, providing a much higher chance of treatment.

Ju Won Kwak - One of the best experts on this subject based on the ideXlab platform.

  • Nanotechnology for Early Cancer Detection
    Sensors, 2010
    Co-Authors: Young Eun Choi, Ju Won Kwak, Joon Won Park
    Abstract:

    Vast numbers of studies and developments in the nanotechnology area have been conducted and many nanomaterials have been utilized to detect Cancers at Early stages. Nanomaterials have unique physical, optical and electrical properties that have proven to be very useful in sensing. Quantum dots, gold nanoparticles, magnetic nanoparticles, carbon nanotubes, gold nanowires and many other materials have been developed over the years, alongside the discovery of a wide range of biomarkers to lower the Detection limit of Cancer biomarkers. Proteins, antibody fragments, DNA fragments, and RNA fragments are the base of Cancer biomarkers and have been used as targets in Cancer Detection and monitoring. It is highly anticipated that in the near future, we might be able to detect Cancer at a very Early stage, providing a much higher chance of treatment.

H. G. Bender - One of the best experts on this subject based on the ideXlab platform.

  • Age of uptake of Early Cancer Detection facilities by low-risk and high-risk patients with familial breast and ovarian Cancer.
    European Journal of Cancer Prevention, 2005
    Co-Authors: Michael P. Lux, Matthias W. Beckmann, R. Bodden-heidrich, H. G. Bender, Sven Ackermann, Caroline Nestle-krämling, Timm O. Goecke, Dieter Niederacher, Mayada R. Bani, Peter A. Fasching
    Abstract:

    INTRODUCTION: Some 5-10% of all cases of breast Cancer and ovarian Cancer have a hereditary genesis. In the setting of an interdisciplinary Cancer genetics clinic, a study of the age at which patients first take advantage of Early Cancer Detection (ECD) facilities was conducted in order to assess the influence of familial risk on health issues. METHODS: The study included 556 women who fulfilled the inclusion criteria (IC) for genetic analysis of the BRCA1 and BRCA2 genes, as well as 205 who did not meet these criteria but attended the primary consultation. RESULTS: Consulters who met the inclusion criteria took advantage of nEarly all methods of ECD at an earlier time than women who did not. A comparison of consulters with or without breast Cancer showed that those without breast Cancer participated in all methods of ECD at an earlier time. CONCLUSION: Methods of improving and increasing participation in ECD facilities, and of encouraging women who are at risk to start on such programs at a younger age, need to be discussed. In this study, familial risk already resulted in a younger age of uptake of ECD facilities.

  • Use of intensified Early Cancer Detection in high-risk patients with familial breast and ovarian Cancer.
    European Journal of Cancer Prevention, 2005
    Co-Authors: Michael P. Lux, R. Bodden-heidrich, H. G. Bender, Sven Ackermann, Caroline Nestle-krämling, Timm O. Goecke, Dieter Niederacher, M. W. Beckmann, Peter A. Fasching
    Abstract:

    A prospective follow-up study was carried out to evaluate the influence of risk and genetic counselling on use of Early Cancer Detection. Five hundred and fifty-six subjects who fulfilled inclusion criteria for a genetic analysis of the BRCA1/2 genes (the high-risk group A) and 205 who did not fulfi

  • Early Cancer Detection programmes for women at high risk for breast and ovarian Cancer: a proposal of practical guidelines.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 1996
    Co-Authors: Matthias W. Beckmann, R. Bodden-heidrich, D. S. Mosny, Crombach G, Nitz U, M. Achnoula, H. G. Bender
    Abstract:

    Women from families with multiple breast and/or ovarian Cancers may be at increased risk to develop breast/ovarian Cancer themselves. Due to personal experience with family members having these diseases they are anxious and ask for specific prophylactic measurements or treatment. The Detection of two susceptibility genes, BRCA1 and BRCA2, has given insight into the genetic background of part of the familial breast/ovarian Cancer syndromes. This has led to an increased demand in genetic counselling, testing, and Early Cancer Detection programmes. Prospective data from Early Cancer Detection programmes in this high risk population are yet not available. Based on data from epidemiological risk studies, breast and ovarian screening programmes and follow up data from breast Cancer trials recommendations for an Early Cancer Detection programme have been summarized. At the present these recommendations are tested in a prospective trial.